Approach to Clinical Trials for the Prevention of Pulmonary Fibrosis
John S. Kim(University of Virginia), Anna J. Podolanczuk(Cornell University), Imre Noth(University of Virginia), Simon Walsh(Royal Brompton & Harefield NHS Foundation Trust), Gary M. Hunninghake(Hubei University of Science and Technology), Luca Richeldi(Coral Reef Alliance), Gísli Jenkins(Imperial College London), Lida P. Hariri(Harvard University), Jonathan A. Kropski(Vanderbilt University), Iván O. Rosas(Brigham and Women's Hospital), Margaret L. Salisbury(Unknown), Sydney B. Montesi(Massachusetts General Hospital), Ayodeji Adegunsoye(University of Chicago), Stephen M. Humphries(National Jewish Health), Athol U. Wells(St Thomas' Hospital), Fernando J. Martínez(University of Massachusetts Chan Medical School)
Cited by 10
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k